HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions

Global clinical-stage biotech x FBDB™ platform and multi-indication development strategy for lead program HCB101 TAIPEI, SHANGHAI, SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.